J
Jerome A. Yesavage
Researcher at Stanford University
Publications - 446
Citations - 43320
Jerome A. Yesavage is an academic researcher from Stanford University. The author has contributed to research in topics: Cognition & Dementia. The author has an hindex of 73, co-authored 423 publications receiving 39527 citations. Previous affiliations of Jerome A. Yesavage include United States Department of Veterans Affairs & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Modeling the effects of obstructive sleep apnea and hypertension in Vietnam veterans with PTSD
Lisa M. Kinoshita,Lisa M. Kinoshita,Jerome A. Yesavage,Jerome A. Yesavage,Art Noda,Booil Jo,Beatriz Hernandez,Joy L. Taylor,Joy L. Taylor,Jamie M. Zeitzer,Jamie M. Zeitzer,Leah Friedman,J. Kaci Fairchild,J. Kaci Fairchild,Jauhtai Cheng,Jauhtai Cheng,Ware G. Kuschner,Ware G. Kuschner,Ruth O'Hara,Ruth O'Hara,Jon-Erik C Holty,Jon-Erik C Holty,Blake K. Scanlon,Blake K. Scanlon +23 more
TL;DR: OSA severity and presence of self-reported hypertension are associated with poor auditory verbal memory and executive function in older adults.
DatasetDOI
Geriatric Depression Scale—Short Form
TL;DR: This survey asks whether you are basically satisfied with your life, and if you feel that your life is empty, and whether you think that most people are better off than you are.
Journal ArticleDOI
Spontaneous mnemonic strategies used by older and younger adults to remember proper names
TL;DR: The results suggest that the use of spontaneous mnemonic strategies may play a role in the difference in proper name recall between younger and older adults.
Journal ArticleDOI
Differential Effects of a List-Learning Mnemonic in Three Age Groups
TL;DR: Results, though indicating the mnemonic to be effective for young and old alike, suggest the development of encoding and retrieval deficits with age.
Journal ArticleDOI
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Paul B. Rosenberg,Lea T. Drye,Anton P. Porsteinsson,Bruce G. Pollock,Devangere P. Devanand,Constantine Frangakis,Zahinoor Ismail,Christopher Marano,Curtis L. Meinert,Jacobo Mintzer,Cynthia A. Munro,Gregory H. Pelton,Peter V. Rabins,Lon S. Schneider,David M. Shade,Daniel Weintraub,Jeffery Newell,Jerome A. Yesavage,Constantine G. Lyketsos +18 more
TL;DR: Changes in agitation outcomes in the placebo arm of a recent trial of citalopram for agitation in Alzheimer's disease (CitAD) report significant placebo response which may be due to regression to the mean, response to a psychosocial intervention, natural course of symptoms, or nonspecific benefits of participation in a trial.